Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OPC1
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I/ Phase II
Sponsor : Lineagen
Deal Size : Undisclosed
Deal Type : Agreement
Details : Lineage and Neurgain will collaborate on the clinical testing of Neurgain’s novel Parenchymal Delivery Injection system, OPC1 , which is designed to allow for the administration of cells to the spinal cord without stopping the patient’s respiration.
Brand Name : OPC1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 08, 2021
Lead Product(s) : OPC1
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I/ Phase II
Sponsor : Lineagen
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?